Proteasis Evaluation in COPD (Pro-BPCO)

Institut National de la Santé Et de la Recherche Médicale, France

Status: Completed

Conditions: Chronic Obstructive Pulmonary Disease

Study type: Observational

Funder types: Other

Identifiers

NCT01713335

C11-56

2012-A00885-38 (Registry Identifier)

Details and patient eligibility

About

The aim of this study was to evaluate kallikreins and its substrate, CCN, in COPD patients. Kallikreins are a subgroup of serine proteases, enzymes which are able to cleave peptide bonds in proteins. Kallicrein profile is unkonwn in COPD. The investigators will assess Kallikrein 1 to 15 and CCN 1 to 6 in sputum of patients. Three groups of patients will be included: Healthy smoker subjects, stable COPD patients and COPD patients with acute exacerbation. Kallicrein levels in sputum will be compared in these groups.

Enrollment: 134 patients

Sex: All

Ages: 50 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for healthy subjects:

• Smoker with tobacco consumption of 20 pack/year
• Normal lung function tests

Exclusion Criteria for healthy subjects:

• diagnosis of lung disease during the study
• Asthma
• Lung cancer
• Pregnant and lactating women

Inclusion Criteria for stable COPD:

• Smoker with tobacco consumption of 20 pack/year
• FEV1/FVC<70% on lung function tests
• no hospitalisation for exacerbation during 3 months before inclusion

Exclusion Criteria for stable COPD:

• Asthma
• Lung cancer
• Pregnant and lactating women

Inclusion Criteria for COPD with exacerbation:

• Smoker with tobacco consumption of 20 pack/year
• worsening of pulmonary symptoms
• FEV1/FVC<70% on lung function tests could be obtain before or 3 months after exacerbation

Exclusion Criteria for COPD with exacerbation:

• Asthma
• Lung cancer
• Pregnant and lactating women